Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1966 1
1973 4
1974 3
1975 12
1976 9
1977 10
1978 21
1979 28
1980 29
1981 36
1982 29
1983 43
1984 39
1985 32
1986 34
1987 45
1988 44
1989 41
1990 48
1991 41
1992 58
1993 61
1994 53
1995 56
1996 47
1997 60
1998 61
1999 86
2000 87
2001 71
2002 86
2003 71
2004 95
2005 85
2006 106
2007 101
2008 115
2009 115
2010 108
2011 117
2012 119
2013 115
2014 116
2015 120
2016 90
2017 72
2018 77
2019 97
2020 106
2021 109
2022 96
2023 100
2024 45

Text availability

Article attribute

Article type

Publication date

Search Results

3,206 results

Results by year

Filters applied: . Clear all
Page 1
S-531011, a Novel Anti-Human CCR8 Antibody, Induces Potent Antitumor Responses through Depletion of Tumor-Infiltrating CCR8-Expressing Regulatory T Cells.
Nagira Y, Nagira M, Nagai R, Nogami W, Hirata M, Ueyama A, Yoshida T, Yoshikawa M, Shinonome S, Yoshida H, Haruna M, Miwa H, Chatani N, Ohkura N, Wada H, Tanaka H. Nagira Y, et al. Among authors: miwa h. Mol Cancer Ther. 2023 Sep 5;22(9):1063-1072. doi: 10.1158/1535-7163.MCT-22-0570. Mol Cancer Ther. 2023. PMID: 37420296 Free PMC article.
S-531011 also depleted human tumor-infiltrating Tregs, but not Tregs derived from human peripheral blood mononuclear cells. These results suggest that S-531011 is a promising drug for inducing antitumor immunity without severe side effects in the clinical setting... …
S-531011 also depleted human tumor-infiltrating Tregs, but not Tregs derived from human peripheral blood mononuclear cells. These res …
Phase III Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastasis: PHOENIX-GC Trial.
Ishigami H, Fujiwara Y, Fukushima R, Nashimoto A, Yabusaki H, Imano M, Imamoto H, Kodera Y, Uenosono Y, Amagai K, Kadowaki S, Miwa H, Yamaguchi H, Yamaguchi T, Miyaji T, Kitayama J. Ishigami H, et al. Among authors: miwa h. J Clin Oncol. 2018 Jul 1;36(19):1922-1929. doi: 10.1200/JCO.2018.77.8613. Epub 2018 May 10. J Clin Oncol. 2018. PMID: 29746229 Clinical Trial.
Patients were randomly assigned at a two-to-one ratio to receive intraperitoneal and intravenous paclitaxel plus S-1 (IP; intraperitoneal paclitaxel 20 mg/m(2) and intravenous paclitaxel 50 mg/m(2) on days 1 and 8 plus S-1 80 mg/m(2) per day on days 1 to 14 for a 3- …
Patients were randomly assigned at a two-to-one ratio to receive intraperitoneal and intravenous paclitaxel plus S-1 (IP; intraperito …
Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer.
Yamada Y, Higuchi K, Nishikawa K, Gotoh M, Fuse N, Sugimoto N, Nishina T, Amagai K, Chin K, Niwa Y, Tsuji A, Imamura H, Tsuda M, Yasui H, Fujii H, Yamaguchi K, Yasui H, Hironaka S, Shimada K, Miwa H, Hamada C, Hyodo I. Yamada Y, et al. Among authors: miwa h. Ann Oncol. 2015 Jan;26(1):141-148. doi: 10.1093/annonc/mdu472. Epub 2014 Oct 14. Ann Oncol. 2015. PMID: 25316259 Free article. Clinical Trial.
BACKGROUND: We evaluated the efficacy and safety of S-1 plus oxaliplatin (SOX) as an alternative to cisplatin plus S-1 (CS) in first-line chemotherapy for advanced gastric cancer (AGC). PATIENTS AND METHODS: In this randomized, open-label, multicenter phase III stud …
BACKGROUND: We evaluated the efficacy and safety of S-1 plus oxaliplatin (SOX) as an alternative to cisplatin plus S-1 (CS) in …
Regulation of Postnatal Cardiomyocyte Maturation by an RNA Splicing Regulator RBFox1.
Huang J, Lee JZ, Rau CD, Pezhouman A, Yokota T, Miwa H, Feldman M, Kong TK, Yang Z, Tay WT, Pushkarsky I, Kim K, Parikh SS, Udani S, Soh BS, Gao C, Stiles L, Shirihai OS, Knollmann BC, Ardehali R, Di Carlo D, Wang Y. Huang J, et al. Among authors: miwa h. Circulation. 2023 Oct 17;148(16):1263-1266. doi: 10.1161/CIRCULATIONAHA.122.061602. Epub 2023 Oct 16. Circulation. 2023. PMID: 37844148 No abstract available.
Worldwide Systematic Review of GSTM1 and GSTT1 Null Genotypes by Continent, Ethnicity, and Therapeutic Area.
Nakanishi G, Pita-Oliveira M, Bertagnolli LS, Torres-Loureiro S, Scudeler MM, Cirino HS, Chaves ML, Miwa B, Rodrigues-Soares F. Nakanishi G, et al. Among authors: miwa b. OMICS. 2022 Oct;26(10):528-541. doi: 10.1089/omi.2022.0090. Epub 2022 Sep 16. OMICS. 2022. PMID: 36112350 Review.
Glutathione S-transferase Mu 1 (GSTM1) and glutathione S-transferase theta 1 (GSTT1) enzymes are glutathione-S-transferases with broad significance for susceptibility or resistance to multifactorial human diseases, as well as detoxification of environmental c …
Glutathione S-transferase Mu 1 (GSTM1) and glutathione S-transferase theta 1 (GSTT1) enzymes are glutathione-S-transfer …
Bell's palsy-induced blepharospasm.
Miwa H, Kondo T, Mizuno Y. Miwa H, et al. J Neurol. 2002 Apr;249(4):452-4. doi: 10.1007/s004150200038. J Neurol. 2002. PMID: 11967652
We report two patients with blepharospasm that appeared during the recovery phase of Bell's palsy. It is well known that hemifacial spasm occasionally appears after Bell's palsy; however, blepharospasm associated with Bell's palsy has been rarely reported so …
We report two patients with blepharospasm that appeared during the recovery phase of Bell's palsy. It is well known that hemifacial s …
Meta-analysis supporting noninferiority of oxaliplatin plus S-1 to cisplatin plus S-1 in first-line treatment of advanced gastric cancer (G-SOX study): indirect comparison with S-1 alone.
Hamada C, Yamada Y, Azuma M, Nishikawa K, Gotoh M, Bando H, Sugimoto N, Nishina T, Amagai K, Chin K, Niwa Y, Tsuji A, Imamura H, Tsuda M, Yasui H, Fujii H, Yamaguchi K, Yasui H, Hironaka S, Shimada K, Miwa H, Hyodo I. Hamada C, et al. Among authors: miwa h. Int J Clin Oncol. 2016 Aug;21(4):668-675. doi: 10.1007/s10147-015-0938-9. Epub 2016 Jan 5. Int J Clin Oncol. 2016. PMID: 26733020 Review.
BACKGROUND: The Randomized Phase III Study Comparing Oxaliplatin plus S-1 with Cisplatin plus S-1 in Chemotherapy-naive Patients with Advanced Gastric Cancer (G-SOX) showed the noninferiority of S-1 (an oral fluoropyrimidine-derivative dihydropyrimidine dehyd …
BACKGROUND: The Randomized Phase III Study Comparing Oxaliplatin plus S-1 with Cisplatin plus S-1 in Chemotherapy-naive Patien …
Carnitine Profile by Tandem Mass Spectrometry and Dialysis Patients.
Kamei D, Kamei Y, Tanaka N, Tsukada M, Miwa N, Hanafusa N, Mineshima M, Nitta K, Tsuchiya K. Kamei D, et al. Among authors: miwa n. Contrib Nephrol. 2019;198:73-77. doi: 10.1159/000496524. Epub 2019 Apr 16. Contrib Nephrol. 2019. PMID: 30991404 Review.
Propafenone associated agranulocytosis.
Miwa LJ, Jolson HM. Miwa LJ, et al. Pacing Clin Electrophysiol. 1992 Apr;15(4 Pt 1):387-90. doi: 10.1111/j.1540-8159.1992.tb05133.x. Pacing Clin Electrophysiol. 1992. PMID: 1374882
Propafenone hydrochloride was approved for marketing by the United States (U.S.) Food and Drug Administration (FDA) in November 1989. During U.S. clinical trials of propafenone, one case of agranulocytosis was seen. Seven additional cases have been reported outside …
Propafenone hydrochloride was approved for marketing by the United States (U.S.) Food and Drug Administration (FDA) in November 1989. …
An adenocarcinoma in an inverted Meckel's diverticulum with intussusception.
Miwa Y, Sato Y, Hirano K, Sunami E, Takahashi M, Kosugi SI, Suda T, Hasegawa G. Miwa Y, et al. Surg Case Rep. 2023 Jun 5;9(1):95. doi: 10.1186/s40792-023-01680-1. Surg Case Rep. 2023. PMID: 37271767 Free PMC article.
BACKGROUND: Adenocarcinoma in an inverted Meckel's diverticulum with intussusception has not been reported to date. ...Based on these characteristics, this tumor is considered to have developed from the ectopic gastric mucosa in a Meckel's diverticulum. CONCLUSIONS: …
BACKGROUND: Adenocarcinoma in an inverted Meckel's diverticulum with intussusception has not been reported to date. ...Based on these …
3,206 results